Compare Heron Therapeutics Inc (HRTX) vs PubMatic Inc (PUBM) Price & Performance

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

PUBM trades at $13.07, up 2.67% today, with a bullish technical signal from moving averages and oversold RSI conditions. The company reported a net loss of -$14.46M in 2025 despite beating Q1 2026 EPS estimates, with revenue at $282.93M. Recent news highlights product launches like AgenticOS and partnerships expanding its AI-powered ad tech reach, while analyst consensus is evenly split between Buy and Hold.

The outlook is mixed: strong cash flow and innovation in AI advertising support growth potential, but persistent negative margins and high P/E of 132 pose valuation risks. Upside exists if upcoming Q2 2026 earnings beat expectations, though competitive and macroeconomic pressures remain headwinds for profitability.